Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. is a drug discovery company that focuses on developing novel psychedelic and non-psychedelic medications to address neuropsychiatric and neurological disorders with unmet medical needs. The company recently entered into a definitive arrangement agreement with Otsuka Pharmaceutical Co., Ltd., signaling a significant acquisition worth approximately CAD $80 million. Mindset's innovative compounds and synthesis processes aim to revolutionize the treatment of psychiatric disorders, contributing to patient care on a global scale.
The Transaction, expected to close in October 2023, marks a strategic move by Otsuka to strengthen its presence in the psychiatry and neurology therapeutic areas. Mindset's shareholders will benefit from the all-cash acquisition, demonstrating a premium value of $0.75 per share. With a focus on maximizing the value of its assets and IP portfolio, Mindset's collaboration with Otsuka is poised to lead to groundbreaking advancements in patient treatment.
In pursuit of its mission to develop next-generation pharmaceutical assets, Mindset is dedicated to creating optimized and patentable psychedelic medicines, leveraging the therapeutic potential of psychedelic drugs. Through proprietary compounds, novel families of psychedelic compounds, and innovative synthesis processes, the company is at the forefront of advancing treatment options for neurological and psychiatric conditions.
On March 14, 2023, Mindset Pharma Inc. (OTCQB: MSSTF) announced that Reunion Neuroscience Inc. has filed a lawsuit against them in the U.S. District Court for New Jersey. The lawsuit claims inventorship and co-ownership of one of Mindset's patents, as well as allegations of inequitable conduct and breach of contract. Mindset firmly denies these allegations and intends to vigorously defend itself in court. The Company focuses on developing novel psychedelic and non-psychedelic medications aimed at treating neuropsychiatric and neurological disorders.
Mindset Pharma (OTCQB: MSSTF) in partnership with PharmAla Biotech has completed the first sale of its cGMP psilocybin to Reset Mind Sciences, a Western Australian company. Reset has received ethics approval for clinical trials on psilocybin-assisted therapy for treatment-resistant depression. Mindset's CEO James Lanthier expressed confidence in the partnership, noting the growing demand for psilocybin in Australia following recent regulatory approvals. PharmAla's CEO, Nick Kadysh, highlighted the increasing pace of research in light of evolving markets.
Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) announced that the United States Patent and Trademark Office has allowed a new patent application, number 17/743,718, covering psilocin derivatives for treating CNS disorders. This marks the fourth patent allowance for Mindset, enhancing its intellectual property portfolio. The Family 1 patent includes psilocybin-inspired candidates with improved pharmacokinetics and safety profiles. The priority date for this application is February 4, 2020. The company focuses on developing next-generation psychedelic medicines for neuropsychiatric disorders.
Mindset Pharma (OTCQB: MSSTF) announced that the USPTO granted allowance for its patent application 17/833,341. This application includes promising compounds like MSP-1014 and MSP-1009, both analogues of psilocybin, which show improved safety and efficacy in pre-clinical studies. These developments signify a step forward in Mindset's goal to address neuropsychiatric disorders with novel medications. CEO James Lanthier emphasized the company's commitment to creating innovative therapeutics, indicating potential for value creation through its expanding intellectual property portfolio.
Mindset Pharma (OTCQB: MSSTF), a drug discovery company focused on next-generation psychedelic treatments for neurological disorders, will participate in two upcoming virtual conferences. CEO James Lanthier and CSO Joseph Araujo will join Stifel GMP’s The Future of Healthcare Conference on December 7, 2022, at 3:30 p.m. ET, and the Canaccord Genuity Symposium on December 13, 2022, at 11:00 a.m. ET. The company aims to address unmet medical needs through its innovative psychedelic compounds and partnerships, including one with the McQuade Center.
Mindset Pharma (MSSTF) announced advancements in its psychedelic drug development pipeline in a letter from CEO James Lanthier. The company aims to optimize psychedelic medications for neuropsychiatric disorders and has made significant strides, including receiving regulatory guidance for its lead candidate MSP-1014. This novel compound is expected to enhance tolerability compared to psilocybin. Additionally, Mindset has established key partnerships, expanded its drug portfolio, and fortified its intellectual property, positioning itself for clinical trials and potential market entry in 2023.
Mindset Pharma Inc. (OTCQB: MSSTF) has entered into an exclusive global sales agreement with PharmAla Biotech Holdings Inc. to provide pharmaceutical-grade psilocybin to licensed clinical researchers. Mindset's patent-pending synthesis process allows for scalable production, crucial for the growing demand in medical psychedelics. This partnership enhances Mindset's commercialization efforts and leverages PharmAla's infrastructure to drive revenue. A large batch of cGMP psilocybin has already been produced, aligning with DEA quotas.
Mindset Pharma Inc. (OTCQB: MSSTF) announced promising results from preclinical studies on its novel prodrug MSP-1014 compared to psilocybin. The research showcased MSP-1014's potential superior tolerability, as evidenced by reduced behavioral changes and better safety profiles in animal models. The prodrug rapidly metabolizes to psilocin, matching psilocybin’s efficacy while potentially minimizing side effects. Presented at Neuroscience 2022, the findings suggest MSP-1014 may effectively address depression in challenging patient populations, with plans to evaluate it in human trials soon.
Mindset Pharma (OTCQB: MSSTF), a drug discovery company, announced important poster presentations for its psilocybin-like candidate, MSP-1014, at two upcoming scientific conferences. The presentations will occur at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston on October 31, 2022, and at Neuroscience 2022 in San Diego on November 13, 2022. Research highlights include preclinical safety and pharmacokinetics studies comparing MSP-1014 and psilocybin.
Mindset Pharma Inc. (OTCQB: MSSTF) announced the selection of two psychedelic drug candidates, MSP-2020 and MSP-2003, for IND enabling studies after successful preclinical testing. These candidates outperform psilocybin, showing a stronger and shorter acting effect, alongside high oral bioavailability. Protected by a USPTO patent, they aim to address mental health disorders. CEO James Lanthier emphasized the milestone in clinical development and the potential these drugs hold for patients in need.
FAQ
What is the market cap of Mindset Pharma (MSSTF)?
What is Mindset Pharma Inc. focused on?
What recent agreement did Mindset Pharma Inc. enter into?
How will the acquisition benefit Mindset Pharma Inc.'s shareholders?
What is the focus of Mindset Pharma Inc.'s drug development programs?
What is the expected timeline for the completion of the Transaction between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.?
How does the collaboration between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd. contribute to patient care?
What sets Mindset Pharma Inc. apart in the pharmaceutical industry?
